Bivalirudin for the treatment of st-segment elevation myocardial infarction: A NICE single technology appraisal

PharmacoEconomics

Volumn 31, Issue 4, 2013, Pages 269-275

  Simpson, E L ^a   Fitzgerald, P ^a   Evans, P ^a   Tappenden, P ^a   Kalita, N ^a   Reckless, J P D ^b   Bakhai, A ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL UNITED HOSPITAL   (United Kingdom)

^c BARNET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PRASUGREL; TIROFIBAN;

BLEEDING; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DRUG COST; DRUG MANUFACTURE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIA; LIFESPAN; MEDICAL TECHNOLOGY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SIMULATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THERAPY EFFECT; UNITED KINGDOM;

EID: 84876899144     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0036-7     Document Type: Review

References (32)

1. National Institute for Health and Clinical Excellence. Guide to the single technology appraisal process. London: NICE; 2009. http://www.nice.org.uk/ media/913/06/Guide-to-the-STA-proof-6-26-10-09.pdf. Accessed 31 Mar 2011.
2. Sculpher M. Single technology appraisal at the UK National Institute for Health and Clinical Excellence: a source of evidence and analysis for decision making internationally. Pharmacoeconomics. 2010;28(5):347-9.
3. Rodgers M, Griffin S, Paulden M, et al. Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal. Pharmacoeconomics. 2010;28(5):351-62.
4. Bagust A, Greenhalgh J, Boland A, et al. Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal. Pharmacoeconomics. 2010;28(6):439-48.
5. Stevenson M, Pandor A. Febuxostat for the management of hyperuricemia in patients with gout: a NICE single technology appraisal. Pharmacoeconomics. 2011;29(2):133-40.
6. Scotland G, Waugh N, Royle P, et al. Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal. Pharmacoeconomics. 2011;29(11):951-61.
7. Dickson R, Bagust A, Boland A, et al. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal. Pharmacoeconomics. 2011;29(12):1051-62.
8. McKenna C, Maund E, Sarowar M, et al. Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(1):35-46.
9. Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(2):137-46.
10. Yang H, Craig D, Epstein D, et al. Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(4):257-70.
11. Boyers D, Jia X, Jenkinson D, et al. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(6):483-95.
12. Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, et al. Omalizumab for severe persistent asthma in children aged 6-11 years: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(11):991-1004.
13. Whyte S, Pandor A, Stevenson M. Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(12):1119-32.
14. Kilonzo M, Hislop J, Elders A, Fraser C, Bissett D, McClinton S, et al. Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma: a NICE single technology appraisal. Pharmacoeconomics. 2013;31(1):15-24.
15. Craig D, Rice S, Paton F, et al. Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation: a NICE single technology appraisal. Pharmacoeconomics. 2013;31(2):101-10.
16. Spackman E, Rice S, Norman G, Suh D-C, Eastwood A, Palmer S. Trastuzumab for the treatment of HER2 positive metastatic gastric cancer: a NICE single technology appraisal. Pharmacoeconomics. 2013;31(3):185-94.
17. Rafia R, Simpson E, Stevenson M, Papaioannou D. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal. Pharmacoeconomics. (in press).
18. Greenhalgh J, Bagust A, Boland A, Blundell M, Oyee J, Beale S, Dundar Y, Hockenhull J, Proudlove C, Chu P. Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma: a NICE single technology appraisal. Pharmacoeconomics. (in press).
19. Armstrong N, Manuela J, van Asselt T, et al. Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal. Pharmacoeconomics. (in press).
20. Tosh J, Archer R, Davis S, et al. Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs: a NICE single technology appraisal. Pharmacoeconomics. (in press).
21. Kearns B, Lloyd-Jones M, Stevenson M, Littlewood C. Cabazitaxel for the second-line treatment of metastatic hormone refractory prostate cancer: a NICE single technology appraisal. Pharmacoeconomics. (in press).
22. Faria R, Spackman E, Burch J, Corbacho B, Todd D, Pepper C, et al. Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: a NICE single technology appraisal. PharmacoEconomics. (in press).
23. National Institute for Health and Clinical Excellence. Myocardial infarction (persistent ST-segment elevation): bivalirudin (TA230). London: NICE; 2011. http://guidance.nice.org.uk/TA230. Accessed 6 Feb 2012.
24. Department of Health, Vascular Programme Team. Treatment of heart attack: national guidance. Final report of the National Infarct Angioplasty Project (NIAP). London: Department of Health and the British Cardiovascular Society; 2008.
25. National Institute for Health and Clinical Excellence. Bivalirudin for the treatment of ST-segment elevation myocardial infarction: final scope. London: NICE; 2010. http://guidance.nice.org.uk/TA/Wave23/27/Scope/pdf/English. Accessed 3 Feb 2011.
26. ®) for the treatment of ST-segment elevation myocardial infarction Manufacturer's submission. Abingdon: The Medicines Company; 2011.
27. National Institute for Health and Clinical Excellence Guide to the methods of technology appraisal. London: NICE; 2008. http://www.nice.org.uk/ media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed 3 Feb 2011.
28. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358(21):2218-30. (Pubitemid 351724451)
29. Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009;374(9696):1149-59.
30. Dauerman HL, Frederick PD, Miller D, French WJ, for the National Registry of Myocardial Infarction. Current incidence and clinical outcomes of bivalirudin administration among patients undergoing primary coronary intervention for stent thrombosis elevation acute myocardial infarction. Coron Artery Dis. 2007;18(2):141-8.
31. Lacey E, Walters S. Continuing inequality: gender and social class influences on self perceived health after a heart attack. J Epidemiol Community Health. 2003;57(8):622-7. (Pubitemid 36930291)
32. Simpson EL, Fitzgerald P, Evans P, Tappenden P, Reckless JPD, Bakhia A, et al. Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a single technology appraisal. Sheffield: ScHARR; 2011.